DK3093345T3 - BACULOVIRUS VECTORS INCLUDING REPEATED CODING SEQUENCES WITH DIFFERENTIAL PREFERRED CODES - Google Patents

BACULOVIRUS VECTORS INCLUDING REPEATED CODING SEQUENCES WITH DIFFERENTIAL PREFERRED CODES Download PDF

Info

Publication number
DK3093345T3
DK3093345T3 DK16176100.2T DK16176100T DK3093345T3 DK 3093345 T3 DK3093345 T3 DK 3093345T3 DK 16176100 T DK16176100 T DK 16176100T DK 3093345 T3 DK3093345 T3 DK 3093345T3
Authority
DK
Denmark
Prior art keywords
coding sequences
baculovirus vectors
vectors including
including repeated
repeated coding
Prior art date
Application number
DK16176100.2T
Other languages
Danish (da)
Inventor
Andrew Christian Bakker
Wilhelmus Theodorus Johannes Maria Christiaan Hermens
Original Assignee
Uniqure Ip Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniqure Ip Bv filed Critical Uniqure Ip Bv
Application granted granted Critical
Publication of DK3093345T3 publication Critical patent/DK3093345T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/864Parvoviral vectors, e.g. parvovirus, densovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14041Use of virus, viral particle or viral elements as a vector
    • C12N2710/14044Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • C12N2750/14152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/50Vectors for producing vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK16176100.2T 2007-07-26 2008-07-25 BACULOVIRUS VECTORS INCLUDING REPEATED CODING SEQUENCES WITH DIFFERENTIAL PREFERRED CODES DK3093345T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95208107P 2007-07-26 2007-07-26
EP07113257 2007-07-26
EP08779058.0A EP2173888B1 (en) 2007-07-26 2008-07-25 Baculoviral vectors comprising repeated coding sequences with differential codon biases

Publications (1)

Publication Number Publication Date
DK3093345T3 true DK3093345T3 (en) 2019-06-24

Family

ID=38753583

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16176100.2T DK3093345T3 (en) 2007-07-26 2008-07-25 BACULOVIRUS VECTORS INCLUDING REPEATED CODING SEQUENCES WITH DIFFERENTIAL PREFERRED CODES
DK08779058.0T DK2173888T3 (en) 2007-07-26 2008-07-25 Baculovirus vectors comprising repeating coding sequences WITH differential preferred codons

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08779058.0T DK2173888T3 (en) 2007-07-26 2008-07-25 Baculovirus vectors comprising repeating coding sequences WITH differential preferred codons

Country Status (20)

Country Link
US (5) US8697417B2 (en)
EP (3) EP2173888B1 (en)
JP (2) JP5634262B2 (en)
KR (1) KR101597695B1 (en)
CN (1) CN101868547B (en)
AU (1) AU2008279883B2 (en)
BR (1) BRPI0814459B1 (en)
CA (1) CA2694406C (en)
DK (2) DK3093345T3 (en)
EA (1) EA022169B1 (en)
ES (1) ES2602585T3 (en)
HK (1) HK1143185A1 (en)
HU (1) HUE029744T2 (en)
IL (1) IL203535A (en)
MX (1) MX2010000944A (en)
NZ (1) NZ582881A (en)
PL (2) PL2173888T3 (en)
PT (1) PT2173888T (en)
SI (2) SI2173888T1 (en)
WO (1) WO2009014445A2 (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022169B1 (en) * 2007-07-26 2015-11-30 ЮНИКЬЮРЕ АйПи Б.В. Insect cell for producing recombinant parvoviral vectors and method for producing recombinant parvoviral virions
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
US9228174B2 (en) * 2010-03-11 2016-01-05 Uniqure Ip B.V. Mutated rep encoding sequences for use in AAV production
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
IT1400425B1 (en) 2010-06-08 2013-05-31 Amsterdam Molecular Therapeutics Bv MODIFIED SNRNAS FOR USE IN THERAPY.
US20140155469A1 (en) * 2011-04-19 2014-06-05 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors and viruses
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
CA2927366A1 (en) 2013-10-24 2015-04-30 Uniqure Ip B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
DK3117005T3 (en) 2014-03-10 2024-08-12 Uniqure Ip Bv Further improved AVV vectors produced in insect cells
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
CN112553229A (en) 2014-11-05 2021-03-26 沃雅戈治疗公司 AADC polynucleotides for treating Parkinson's disease
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
RU2020108189A (en) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. COMPOSITIONS AND METHODS OF TREATMENT OF LATERAL AMYOTROPHIC SCLEROSIS (ALS)
MX2017006217A (en) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Modulatory polynucleotides.
EP3224376B2 (en) 2014-11-28 2023-04-26 uniQure IP B.V. Dna impurities in a composition comprising a parvoviral virion
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
HUE043842T2 (en) 2014-12-24 2019-09-30 Uniqure Ip Bv Rnai induced huntingtin gene suppression
AU2017254652B2 (en) * 2016-04-21 2022-12-01 Virovek, Inc. AAV production in insect cells, methods and compositions therefor
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017201258A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
CN117904112A (en) 2016-05-18 2024-04-19 沃雅戈治疗公司 Regulatory polynucleotides
IL263801B2 (en) 2016-07-26 2024-01-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
CN110225975A (en) 2016-08-23 2019-09-10 阿库斯股份有限公司 For treating the composition and method of non-age-dependent hearing impairment in people experimenter
CN110650673B (en) 2016-08-30 2024-04-09 加利福尼亚大学董事会 Methods for biomedical targeting and delivery and devices and systems for practicing the methods
AU2017378191A1 (en) 2016-12-16 2019-07-04 Uniqure Ip B.V. Immunoadsorption
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
SG11201909868YA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
EA202090260A1 (en) 2017-07-10 2020-05-08 ЮНИКЬЮРЕ АйПи Б.В. MEANS AND METHODS FOR HUMAN AAV GENOTHERAPY
JP7229989B2 (en) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド Trajectory array guide system
TWI722310B (en) 2017-08-03 2021-03-21 美商航海家醫療公司 Compositions and methods for delivery of aav
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
JP7502991B2 (en) 2017-10-16 2024-06-19 ボイジャー セラピューティクス インコーポレイテッド Treatment of amyotrophic lateral sclerosis (ALS)
WO2019129859A1 (en) 2017-12-29 2019-07-04 Uniqure Ip B.V. Modified viral vectors and methods of making and using the same
SG11202006056RA (en) 2018-01-17 2020-07-29 Meiragtx Uk Ii Ltd A modified raav capsid protein for gene therapy
EP3793616A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
US12060567B2 (en) 2018-06-13 2024-08-13 Voyager Therapeutics, Inc. Engineered untranslated regions (UTR) for AAV production
AU2019299861A1 (en) 2018-07-02 2021-01-14 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
CN112770812A (en) 2018-07-24 2021-05-07 沃雅戈治疗公司 System and method for producing gene therapy formulations
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
EP3850098A1 (en) 2018-09-12 2021-07-21 uniQure IP B.V. Rnai induced c9orf72 suppression for the treatment of als/ftd
US20220125073A1 (en) * 2018-09-20 2022-04-28 Tallgrass Biologics L.L.C. Treatment and control of colony collapse disorder
CN109295172A (en) * 2018-09-26 2019-02-01 浙江海洋大学 The codon preference analysis method of Larimichthys crocea scavenger receptor family gene
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
CN113166731A (en) 2018-10-05 2021-07-23 沃雅戈治疗公司 Engineered nucleic acid constructs encoding AAV production proteins
US20210371470A1 (en) 2018-10-12 2021-12-02 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
US20210395777A1 (en) 2018-10-15 2021-12-23 Voyager Therapeutics, Inc. EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
WO2020104480A1 (en) 2018-11-19 2020-05-28 Uniqure Biopharma B.V. Adeno-associated virus vectors for expressing fviii mimetics and uses thereof
AU2019382824A1 (en) 2018-11-19 2021-06-03 Uniqure Ip B.V. Method and means to deliver miRNA to target cells
CN113383077A (en) 2018-11-19 2021-09-10 优尼科Ip有限公司 RNAi-induced ataxin-3 reduction for treatment of spinocerebellar ataxia type 3
AU2019385638A1 (en) 2018-11-19 2021-06-03 Uniqure Ip B.V. A companion diagnostic to monitor the effects of gene therapy
CA3125770A1 (en) 2019-01-18 2020-07-23 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
TW202106879A (en) 2019-04-29 2021-02-16 美商航海家醫療公司 Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
MX2022000551A (en) 2019-07-15 2022-05-18 Meiragtx Uk Ii Ltd Modified aav capsid proteins for treatment of arthritic disease.
US20220290182A1 (en) 2019-08-09 2022-09-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2021041485A1 (en) 2019-08-26 2021-03-04 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2021041375A1 (en) * 2019-08-26 2021-03-04 Rootpath Genomics, Inc. Compositions and methods for producing adeno-associated viral vectors
WO2021053018A1 (en) 2019-09-16 2021-03-25 Uniqure Ip B.V. Targeting misspliced transcripts in genetic disorders
MX2022010050A (en) 2020-02-21 2022-09-05 Akouos Inc Compositions and methods for treating non-age-associated hearing impairment in a human subject.
WO2021195491A2 (en) * 2020-03-26 2021-09-30 Asklepios Biopharmaceutical, Inc. Inducible promoter for viral vector production
WO2021198510A1 (en) 2020-04-02 2021-10-07 Uniqure Biopharma B.V. Novel cell line
JP2023519502A (en) 2020-04-02 2023-05-11 ユニキュアー バイオファーマ ビー.ブイ. Dual bifunctional vectors for AAV production
JP2023521347A (en) 2020-04-07 2023-05-24 ユニキュアー アイピー ビー.ブイ. Genetic constructs and uses thereof for silencing angiopoietin-like 3 (ANGPTL3)
JP2023523401A (en) 2020-04-15 2023-06-05 ボイジャー セラピューティクス インコーポレイテッド Tau binding compound
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
MX2023000815A (en) 2020-07-27 2023-04-11 Voyager Therapeutics Inc Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency.
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP4301768A2 (en) 2021-03-03 2024-01-10 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
EP4305157A1 (en) 2021-03-09 2024-01-17 Huidagene Therapeutics (Singapore) Pte. Ltd. Engineered crispr/cas13 system and uses thereof
WO2022214635A1 (en) 2021-04-08 2022-10-13 Stichting Vu Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders
AU2022285138A1 (en) 2021-06-02 2023-11-30 Uniqure Biopharma B.V. Adeno-associated virus vectors modified to bind high-density lipoprotein
US20240240206A1 (en) 2021-06-02 2024-07-18 Uniqure Biopharma B.V. Insect cell production of parvoviral vectors with modified capsid proteins
JP2024523445A (en) 2021-06-21 2024-06-28 ユニキュアー バイオファーマ ビー.ブイ. Genetic constructs for silencing alpha-synuclein and uses thereof - Patents.com
US20240287545A1 (en) 2021-06-21 2024-08-29 Uniqure Biopharma B.V. Improved lysis procedures
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
EP4392434A1 (en) 2021-08-26 2024-07-03 uniQure biopharma B.V. Insect cell-produced high potency aav vectors with cns-tropism
WO2023091949A2 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2023147374A2 (en) 2022-01-25 2023-08-03 Voyager Therapeutics, Inc. Baculovirus expression system
CN114703203B (en) * 2022-02-11 2024-08-06 上海渤因生物科技有限公司 Baculovirus vector and use thereof
WO2023198745A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of apoe
WO2023198663A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of snca
WO2023198662A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Novel systems for nucleic acid regulation
WO2023198702A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of c9orf72
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2024163012A1 (en) 2023-02-02 2024-08-08 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2024218192A1 (en) 2023-04-18 2024-10-24 Uniqure Biopharma B.V. Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
WO2024218190A1 (en) 2023-04-18 2024-10-24 Uniqure Biopharma B.V. Generation of adeno-associated virus capsid libraries for insect cells
WO2024218204A1 (en) 2023-04-18 2024-10-24 Uniqure Biopharma B.V. Gene delivery vehicles comprising rna and antibodies
WO2024226761A2 (en) 2023-04-26 2024-10-31 Voyager Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5871974A (en) * 1990-09-28 1999-02-16 Ixsys Inc. Surface expression libraries of heteromeric receptors
NZ308772A (en) * 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
FR2774699B1 (en) 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa METHOD FOR REDUCING HOMOLOGATED RECOMBINATION EVENTS
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
AU5799200A (en) 1999-06-24 2001-01-31 Academic Hospital At The University Of Amsterdam Lpl variant therapeutics
AU781478B2 (en) * 1999-08-20 2005-05-26 Johns Hopkins University School Of Medicine, The Methods and compositions for the construction and use of fusion libraries
US20020045264A1 (en) * 2000-03-14 2002-04-18 During Matthew J. Production of chimeric capsid vectors
US20030129203A1 (en) * 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
EP1572893B1 (en) 2001-11-09 2009-01-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES Production of adeno-associated virus in insect cells
CA2369985A1 (en) * 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
WO2003068163A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
AU2003212708A1 (en) 2002-03-05 2003-09-16 Stichting Voor De Technische Wetenschappen Baculovirus expression system
DE10260805A1 (en) 2002-12-23 2004-07-22 Geneart Gmbh Method and device for optimizing a nucleotide sequence for expression of a protein
US20070275449A1 (en) * 2003-10-15 2007-11-29 Vector Gene Technology Company Ltd. Method for Large-Scale Production, Isolation, Purification and the Uses of Multi-Type Recombinant Adeno-Associated Virus Vectors
WO2005072364A2 (en) 2004-01-27 2005-08-11 University Of Florida A modified baculovirus expression system for production of pseudotyped raav vector
CA2575490A1 (en) 2004-08-03 2006-02-16 Frank Notka Method for modulating gene expression by altering the cpg content
PL1945779T3 (en) * 2005-10-20 2013-08-30 Uniqure Ip Bv Improved aav vectors produced in insect cells
WO2007084773A2 (en) * 2006-01-20 2007-07-26 University Of North Carolina At Chapel Hill Enhanced production of infectious parvovirus vectors in insect cells
WO2007148971A2 (en) 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
EA022169B1 (en) * 2007-07-26 2015-11-30 ЮНИКЬЮРЕ АйПи Б.В. Insect cell for producing recombinant parvoviral vectors and method for producing recombinant parvoviral virions

Also Published As

Publication number Publication date
EP3093345A1 (en) 2016-11-16
EP3093345B8 (en) 2019-07-24
NZ582881A (en) 2012-04-27
EA022169B1 (en) 2015-11-30
US8697417B2 (en) 2014-04-15
CN101868547B (en) 2016-03-16
JP5634262B2 (en) 2014-12-03
IL203535A (en) 2016-02-29
DK2173888T3 (en) 2016-11-28
EP2173888A2 (en) 2010-04-14
US20190203183A1 (en) 2019-07-04
HUE029744T2 (en) 2017-04-28
US20220251520A1 (en) 2022-08-11
BRPI0814459A2 (en) 2014-10-21
PT2173888T (en) 2016-11-17
CA2694406C (en) 2019-03-26
BRPI0814459B1 (en) 2023-01-24
CA2694406A1 (en) 2009-01-29
US20140186926A1 (en) 2014-07-03
HK1143185A1 (en) 2010-12-24
SI3093345T1 (en) 2019-08-30
EA201070184A1 (en) 2010-08-30
JP2010534472A (en) 2010-11-11
WO2009014445A3 (en) 2009-04-30
CN101868547A (en) 2010-10-20
EP2173888B1 (en) 2016-08-17
WO2009014445A2 (en) 2009-01-29
EP3561063A1 (en) 2019-10-30
EP3093345B1 (en) 2019-04-24
US20100261254A1 (en) 2010-10-14
MX2010000944A (en) 2010-08-31
KR20100065284A (en) 2010-06-16
ES2602585T3 (en) 2017-02-21
US9580691B2 (en) 2017-02-28
US11306291B2 (en) 2022-04-19
US20160032254A1 (en) 2016-02-04
SI2173888T1 (en) 2017-01-31
KR101597695B1 (en) 2016-02-25
PL3093345T3 (en) 2020-03-31
PL2173888T3 (en) 2017-02-28
US10190098B2 (en) 2019-01-29
AU2008279883A1 (en) 2009-01-29
IL203535A0 (en) 2011-07-31
JP2014239686A (en) 2014-12-25
AU2008279883B2 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
DK3093345T3 (en) BACULOVIRUS VECTORS INCLUDING REPEATED CODING SEQUENCES WITH DIFFERENTIAL PREFERRED CODES
BRPI0918426A2 (en) multi-colored codes
DK2115143T3 (en) BUTTIAUXELLA SP.-PHYTHASE VARIETIES WITH CHANGED PROPERTIES
ZA201009013B (en) Bronchoalveolar lavage catheter assembly
DK3484076T3 (en) Computationally efficient convolutional coding with rate matching
BRPI0911849A2 (en) sunscreens
BRPI0816900A2 (en) User Equipment
DK2122102T3 (en) Flexible curtain design
DE602008003253D1 (en) sliding element
DE602005012822D1 (en) NMR-RF-COILS WITH SHIFTED MOVABLE CAPACITY-TAPES
BRPI0916202A2 (en) umbilical cord
BRPI0820420A2 (en) Tubing
DE502006003047D1 (en) rubber sleeve
PL381556A1 (en) The manner of obtaining of modified (poly)siloxans
HUE043953T2 (en) Baculoviral vectors comprising repeated coding sequences with differential codon biases
TH94233B (en) Rubber cross-section
GB0808017D0 (en) shRHA sequences
ES1065910Y (en) LINEAR CARP
DK200700225U1 (en) Chemical compound with useful properties
ES1068259Y (en) TUBULAR CELOSIA
ITCH20060019A1 (en) CODE DETECTOR-SENSOR
UA15442S (en) PROFILE
UY3749Q (en) PROFILE
UA17341S (en) PROFILE
UA17340S (en) PROFILE